Retina Regeneration Therapy effective in ME

Article

Ellex's 2RT, a Retina Regeneration Therapy, is safe and effective in the treatment of macular oedema (ME) secondary to diabetic retinopathy (DR), according to study results presented at this year's American Academy of Ophthalmology meeting.

Ellex 2RT, a Retina Regeneration Therapy, is safe and effective in the treatment of macular oedema (ME) secondary to diabetic retinopathy (DR), according to study results presented at this year's American Academy of Ophthalmology meeting. Ellex 2RT uses a green YAG laser to target the retinal pigment epithelium with 532 nm light energy, delivered in three-nanosecond pulses.

Professor John Marshall, PhD, FRCPath, FRCOphth (Hons), of St. Thomas' Hospital, London, UK, and colleagues treated the newly-diagnosed diabetic maculopathy of 23 patients (eyes, n=38) with Ellex 2RT to modify the macular grid pattern. Of the patients enrolled in the trial, 17 eyes (n=28) completed the six-month follow-up period.

At the six-month follow-up visit, central macular thickness had decreased by ≥5% from baseline in 46% of patients; it remained stable in 39% of patients and increased by ≥5% in the remaining 15%. Hard exudates were decreased in >50% of treated eyes. An improvement of ≥2 lines of LogMar visual acuity was observed in 43% of eyes; of 1–2 lines, in 28%. Visual acuity remained stable in 15% of eyes and decreased in 14%.

The device's manufacturers, Ellex, now plans to investigate the role of Ellex 2RT as a therapeutic in other indications, including age-related macular degeneration and central serous retinopathy.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.